Last reviewed 2026-04-20 · How we verify

GIOTRIF 30mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhoea
• Rash
• Stomatitis
• Paronychia
• Decreased appetite
• Pruritus
• Nausea

Key clinical trials

• Observational Study of Afatinib 30 mg Daily
• Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (PHASE2)
• The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
• Phase II Umbrella Study Directed by Next Generation Sequencing (PHASE2)
• To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion (PHASE4)
• GIOTRIF rPMS in Korean Patients With NSCLC
• To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation (PHASE4)
• Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.